The public health impact of extending the catch-up nonavalent human papillomavirus vaccination program to 2028 in Japan: a model-based study
Routine vaccination in combination with an extension of the catch-up HPV vaccination strategy for females 17-26 years of age from three to six years may expedite the decrease of morbidity and mortality due to HPV-related diseases in Japan.
Authors
- Cody Palmer (ORCID: https://orcid.org/0000-0002-9060-5999)
- Xuedan You (ORCID: https://orcid.org/0000-0002-2551-9111)
- I. Diakité (ORCID: https://orcid.org/0000-0001-7151-4330)
- Keisuke Tobe (ORCID: https://orcid.org/0000-0003-2761-4531)
- Taizo Matsuki (ORCID: https://orcid.org/0000-0002-0591-4261)
- Ya‐Ting Chen (ORCID: https://orcid.org/0009-0001-3189-7426)
Institutions
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- MSD K.K. (Japan) (JP)
- Decision Sciences (United States) (US)
Publication Details
- Journal
- BMC Public Health
- Published
- 2025-12-06
- DOI
- https://doi.org/10.1186/s12889-025-25684-8
- Primary Topic
- Cervical Cancer and HPV Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00